We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Faron Pharmaceuticals Oy | FARN | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -2.50 | -1.45% | 170.00 | 08:05:15 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 172.50 | 170.00 | 172.50 | 170.00 | 172.50 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 27/8/2024 14:31 by citys2874 FARN AND INDI BREAKING OUT NOW |
Posted at 17/11/2020 12:33 by sharesoc The presentation packs and recording from our webinar with Faron Pharma on 3rd Nov can be found here for full members to view: To access the presentation, you'll need to be a full member of ShareSoc, which is a not-for-profit organisation that supports individual shareholders and campaigns for shareholder rights. If you're not already a member you can join here: hxxps://www.sharesoc Once you've joined, you'll receive an invitation to register for our "members network" private social network, from where you'll be able to access the presentation (and presentations on 100s of other meetings). If you're already a member and have any difficulty accessing the report, please do not hesitate to contact us here: hxxps://www.sharesoc |
Posted at 25/10/2020 13:29 by sharesoc Potential investors and current shareholders may be interested in our webinar with Faron Pharmaceuticals (FARN), 3 November 2020 |
Posted at 16/10/2020 09:59 by toffeeman This is Farn IV I think“ Solidarity’s “most disappointing results,” however, are those for interferon-beta, says Topol. Mortality among the 2050 people who received that drug (either alone or in combination with lopinavir/ritonavir) was 11.9%, versus 10.5% in the control group". |
Posted at 20/7/2020 16:16 by diversification They did say that, but was that an opinion or stated fact backed up with trial results? I'm not looking to argue with you, I also managed to financially benefit from the rise in SNG, but the conference call was less than impressive imo. Good luck with your investment, I assume you also hold FARN to be positing here? |
Posted at 04/5/2020 15:32 by timberwolf3 Strange that it's so quiet here considering what they potentially have, i assume it will not be long before FARN is in the spotlight. |
Posted at 04/5/2020 13:32 by toffeeman hash - it's completely different FARN is an injectible SNG is nebulised(I hold both) |
Posted at 01/4/2020 08:32 by bwgs So did I Daffodil, any positive on the back of this though should motor us upwards.Market generally in the red today which doesn't help matters either. Great opportunity for FARN now |
Posted at 26/2/2020 23:31 by bwgs Thank you for your reply.To date I have to say I'm very encouraged as an investor in the way Farn is moving.In respect of 3rd party funding, it may well be that Farn are being very cautious, and not willing to dilute to high heaven (which is what usually happens on AIM).Would be great to see this going back to £8+ |
Posted at 08/2/2020 15:01 by nobbygnome I heard the presentation on Thursday at Proactive. I have to say I am quite impressed with the Clevegen antibody and was interested to hear the results of the ongoing open label trial will be released in March. From what I saw and my knowledge of a similar drug, I think it has a good chance of working. So FARN might be worth a punt on the back of this result and I will be watching for a suitable buy point.Just a comment about Traumakine and the steroid issue. Synairgen clearly got to grips with this problem because in their ongoing inhaled beta interferon trial in COPD with viral infections they excluded patients who had been on oral steroids in the last 6 weeks. I think that trial has a very high chance of a successful outcome.... |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
